Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
8132 8186 8251 8037 8039 Last
685500 561300 593000 993000 904500 Volume
-0.09% +0.66% +0.79% -2.59% +0.02% Change
Estimated financial data (e)
Sales 2022 695 B 6 121 M 6 121 M
Net income 2022 55 696 M 491 M 491 M
Net cash position 2022 155 B 1 367 M 1 367 M
P/E ratio 2022 41,4x
Yield 2022 2,01%
Sales 2023 732 B 6 448 M 6 448 M
Net income 2023 58 586 M 516 M 516 M
Net cash position 2023 159 B 1 398 M 1 398 M
P/E ratio 2023 39,3x
Yield 2023 2,14%
Capitalization 2 305 B 20 267 M 20 304 M
EV / Sales 2022 3,09x
EV / Sales 2023 2,93x
Nbr of Employees 11 237
Free-Float 87,9%
More Financials
Company
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Ratings of Eisai Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about EISAI CO., LTD.
10/21BIOARCTIC : Interim Report for the period July - September 2021
AQ
10/18Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University
CI
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
PU
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
09/29EISAI CO., LTD. : Ex-dividend day for interim dividend
FA
09/28EISAI : Starts Rolling Submission To Seek US Approval For Alzheimer's Disease Therapy
MT
09/27EISAI : INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF ..
PU
09/27BIOARCTIC : Eisai initiates rolling submission for the US FDA Biologics license applicatio..
AQ
09/27BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics Lice..
CI
09/27Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of..
CI
09/27EISAI : Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
AQ
09/27EISAI : Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approva..
PU
09/22EISAI : Italy awarded highest classification at sixth annual welfare index pmi* in italy
PU
09/21EISAI : Latest Value Creation Report (Former Integrated Report)
PU
More news
News in other languages on EISAI CO., LTD.
10/15Merck & Co erhält EU-Zulassungsemfehlung bei Krebsmittel
09/10Le Nikkei 225 progresse de 1,3 % en raison de la perspective d'une extension des mesure..
09/07Citius Pharmaceuticals acquiert les droits de l'immunothérapie oncologique E7777 auprès..
07/16MÄRKTE ASIEN/Mehrheitlich Abgaben - Technologiewerte unter Druck
07/16Tokyo toujours perturbée par la situation sanitaire au Japon
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 039,00 JPY
Average target price 11 681,54 JPY
Spread / Average Target 45,3%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.9.05%20 267
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979